By Brazil Stock Guide — Hapvida (B3: HAPV3), one of Brazil’s largest private health insurance operators, has broadened its review of assets as part of efforts to strengthen its capital structure and expects to see early signs of an operational recovery in the fourth quarter of 2026. The company anticipates that its ongoing restructuring initiatives will deliver more substantial results starting in the first half of 2027.
Hapvida shares were up nearly 15% around midday on Thursday (November 12), as investors assessed the company’s quarterly results and the outlook presented by management.
During the third-quarter earnings call, CEO Luccas Adib said the company was making progress on three priorities: reducing debt, restoring profitability and improving the experience of its health plan members.
“Some of the decisions we made in 2024 and 2025 only showed up in our 2026 results. Similarly, much of what we are doing now should have a stronger impact starting in the first half of 2027,” Adib said.
According to the executive, there is a natural lag between implementing operational changes and seeing their financial benefits. Contract renegotiations depend on individual renewal cycles, while resizing the company’s network of hospitals and clinics and streamlining administrative operations involve upfront costs before generating recurring savings.
One of the key developments disclosed during the call was an expansion of the mandates given to investment banks advising Hapvida on potential asset divestitures. Asked by BTG Pactual whether the company was considering transactions beyond its operations in southern Brazil, Adib confirmed that the original mandates had been revised.
“We have changed the scope of the initial mandates,” he said. The company is now conducting a broader assessment of its asset portfolio to identify opportunities to improve its financial position. Management did not specify which assets might be sold, the potential transaction values or a timetable for any deals.
Reducing leverage remains a priority. Net debt stood at R$5.3 billion at the end of September, down slightly more than R$100 million during the quarter. Hapvida also highlighted the benefits of repurchasing debt securities at a discount and improving working capital management. According to management, the company maintains more than R$5 billion in freely available cash.
On the commercial side, Hapvida continues to review unprofitable contracts and adjust its pricing strategy. About 26% of the group of contracts initially identified for review has already been addressed. The company is prioritizing portfolio profitability over membership growth for its own sake.
Early effects of that strategy are becoming visible in revenue. In the third quarter, the average premium per health plan member rose 7%, helping net revenue increase nearly 4% to R$8.1 billion despite a decline in membership. The small and medium-sized business segment, which management considers more profitable, added more than 10,000 members organically during the period.
Hapvida is also resizing its network of hospitals and clinics to bring capacity more closely in line with regional demand. At the same time, the company is renegotiating supplier contracts, digitizing processes and deploying artificial intelligence across administrative and healthcare operations. In hospital billing, for example, AI tools now handle a significant share of the workload, allowing the department to operate with 75% fewer employees.
As part of its cost discipline measures, Adib also announced that Hapvida’s board of directors had voluntarily decided to cut its total compensation by 50% for 2027. The CEO presented the decision as a demonstration of the board’s commitment to the company’s restructuring efforts.
Legal disputes remain a significant challenge, although management expects the situation to begin improving in the coming months. Hapvida has overhauled its legal processes, expanded the use of data in decision-making and is reviewing court-ordered deposits and provisions for legal liabilities. According to Adib, judicial account freezes declined in October, although he cautioned that one month of improvement was not enough to establish a sustained trend.
The company is also working to reduce customer complaints and improve services for members. Initiatives include streamlining medical authorization procedures, strengthening digital channels and introducing mechanisms to resolve disputes before they escalate into regulatory complaints or court proceedings.
Despite the progress outlined by management, financial results continue to reflect the costs of the transition. Adjusted EBITDA totaled R$497 million in the third quarter, with a margin of 6.1%, compared with 9.6% a year earlier. Adjusted net income reached R$107 million, while the company reported a statutory net loss of R$119 million.
Adib acknowledged that results remain below levels management considers acceptable but said commercial, operational and administrative initiatives should support a gradual recovery in margins. Hapvida plans to provide greater visibility into the recurring financial benefits expected in 2027 during its next earnings call.
“We are not asking for patience. We are asking you to hold us accountable for the milestones I have just outlined,” Adib said, emphasizing that restoring Hapvida’s credibility will depend on delivering measurable improvements quarter after quarter.
Leave a Reply